Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

UBS Sees a 'Buying Opportunity' in Human Genome


UBS Warburg sees a buying opportunity in Human Genome Sciences (HGSI).

Analyst Meirav Chovav says the company announced that its Phase II trial of topical Repifermin in venous ulcers did not meet its goals, and says it will discontinue developing the drug for this indication. Chovav believes the discontinuation of Repifermin in wound healing will allow Human Genome to focus resources in more promising areas of its pipeline.

She says she's optimistic about the LymphoStat-B program in lupus. Also, Chovav believes any weakness in Human Genome shares represents a buying opportunity. She maintains her buy rating and $19 target.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus